A new cancer therapy uses the herpes virus to fight harmful cells. The modified virus infects cancer cells, causing them to explode, while alerting the immune system. The therapy is in the early stages of trials but looks very promising, according to cancer researchers. Loading Something is loading. A new cancer therapy that uses an …
FILE PHOTO: A patient undergoes positron emission tomography.Photo by Vladimir Smirnov\TASS via Getty Images A new cancer therapy uses the herpes virus to fight harmful cells. The modified virus infects cancer cells, causing them to explode, while alerting the immune system. The therapy is in the early stages of trials but looks very promising, according …
FILE PHOTO: A patient undergoes positron emission tomography.Photo by Vladimir Smirnov\TASS via Getty Images A new cancer therapy uses the herpes virus to fight harmful cells. The modified virus infects cancer cells, causing them to explode, while alerting the immune system. The therapy is in the early stages of trials but looks very promising, according …
After years of studying the way Americans eat and the myriad health problems that stem from crummy diets, lead researcher Susan Roberts said it’s time to get pragmatic. “We can be purists and say everyone should have the perfect diet, but the reality is that for most people it won’t work for them,” said Roberts, …
The full names and academic degrees of the authors are as follows: Steven J. Russell, MD, Ph.D., Roy W. Beck, MD, Ph.D., Edward R. Damiano, Ph.D., Firas H. El-Khatib, Ph.D., Katrina J. Ruedy, MSPH, Courtney A. Balliro, RN, CDCES, CRN-BC, Zoey Li, MS, Peter Calhoun, Ph.D., R. Paul Wadwa, MD, Bruce Buckingham, MD, Keren Zhou, …
Randomized multicenter trial of a bionic pancreas in type 1 diabetes | NEJM Read More »
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared to a placebo, drugmakers Biogen and Eisai said on Tuesday. The drug, tested in a global Phase 3 clinical trial, also met all secondary endpoints, showing “target engagement” with reduced levels of amyloid – a …
An experimental drug for Alzheimer’s disease slowed cognitive and functional decline by 27% in a closely monitored clinical trial, the drug’s sponsors said on Tuesday, boosting the therapy’s chances of approval earlier this year. next. Japanese drugmaker Eisai and its US partner, Biogen, said in a press release that the slowing of deterioration, compared to …
Experimental Alzheimer’s drug slows cognitive decline in trial, companies say Read More »
An Biogen and Eisai’s experimental Alzheimer’s disease treatment slowed the rate of cognitive decline by 27% in a clinical trial, the companies said on Tuesday, meeting the goals of a closely watched study and bolstering the case of the drug for approval as early as January. The positive result is good news for the millions …
Press release Wednesday, September 21, 2022 NIH-funded researchers complete first study comparing drugs commonly used for type 2 diabetes. In a large clinical trial directly comparing four drugs commonly used to treat type 2 diabetes, researchers found that insulin glargine and liraglutide were the best of the four drugs approved by the United States Food …
Two Popular Diabetes Drugs Outperformed Others in Massive Clinical Trial Read More »
Five critically ill lupus patients saw their disease go into remission after a single infusion of modified immune cells, in a small trial that borrows from cancer therapy to harness patients’ own cells to treat the autoimmune disease . Scientists are call the “dramatic” and “incredibly exciting” results, saying the findings could herald a new …
Lupus patients go into remission in ‘spectacular’ immunotherapy trial Read More »
